Other languages Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Real-time Estimate Cboe BZX Other stock markets 09:31:31 2024-06-11 am EDT			5-day change	1st Jan Change
6.44 ^USD	-1.53%		-3.96%	-42.83%

Jun. 10	Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing	MT
May. 22	Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Ironwood Pharmaceuticals Insider Sold Shares Worth $517,694, According to a Recent SEC Filing	Jun. 10
Ironwood Pharmaceuticals Insider Sold Shares Worth $436,136, According to a Recent SEC Filing	May. 22
Ironwood Pharmaceuticals, Inc. Presents Late-Breaking Data During the 2024 Digestive Disease Week Meeting from Its Pivotal Phase III Clinical Trial, STARS	May. 21
Sector Update: Health Care Stocks Higher Late Afternoon	May. 09
Sector Update: Health Care Stocks Gain in Thursday Afternoon Trading	May. 09
Sector Update: Health Care	May. 09
Ironwood Pharmaceuticals' Shares Fall After Q1 Swings to a Non-GAAP Loss, Revenue Declines; 2024 Revenue Guidance Cut	May. 09
Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024	May. 09
Ironwood Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
La biotech helvétique a profité d'un regain de fonds en 2023	Apr. 23
Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)	Mar. 28
Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	Feb. 29
Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	Feb. 29
Top Premarket Decliners	Feb. 29
Ironwood says bowel disease treatment meets main goal in late-stage trial	Feb. 29
Ironwood Pharmaceuticals Insider Sold Shares Worth $2,699,979, According to a Recent SEC Filing	Feb. 15
Ironwood Pharmaceuticals Insider Sold Shares Worth $588,538, According to a Recent SEC Filing	Feb. 15
Ironwood Pharmaceuticals Insider Sold Shares Worth $722,071, According to a Recent SEC Filing	Feb. 15
Ironwood Pharmaceuticals Q4 Non-GAAP Net Income Drops, Revenue Rises	Feb. 15
Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ironwood Pharmaceuticals, Inc.

Equities

IRWD

US46333X1081

Other languages

Filters